AngioDynamics Inc. (ANGO) Updates FY17 Earnings Guidance
AngioDynamics Inc. (NASDAQ:ANGO) updated its FY17 earnings guidance on Wednesday. The company provided earnings per share guidance of $0.62-0.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.63. The company issued revenue guidance of $355-360 million, compared to the consensus revenue estimate of $359.18 million.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised AngioDynamics from a sell rating to a hold rating in a research note on Monday, July 25th. KeyCorp set a $18.00 target price on AngioDynamics and gave the company a buy rating in a research note on Monday, September 12th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $15.20.
AngioDynamics Inc. (NASDAQ:ANGO) opened at 17.30 on Wednesday. The firm’s 50-day moving average price is $16.76 and its 200-day moving average price is $14.25. The company’s market cap is $630.10 million. AngioDynamics Inc. has a 52-week low of $9.71 and a 52-week high of $17.64.
AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Wednesday, October 5th. The company reported $0.17 EPS for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.04. The business had revenue of $88.10 million for the quarter, compared to analysts’ expectations of $86.06 million. AngioDynamics had a positive return on equity of 3.94% and a negative net margin of 12.57%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $0.11 earnings per share. On average, equities analysts anticipate that AngioDynamics Inc. will post $0.63 EPS for the current year.
In other news, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of AngioDynamics stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,763,420.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David F. Burgstahler sold 2,250,000 shares of AngioDynamics stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,895,000.00. Following the completion of the sale, the director now directly owns 23,988 shares in the company, valued at $350,704.56. The disclosure for this sale can be found here. Company insiders own 1.88% of the company’s stock.
Several large investors have recently modified their holdings of the company. C M Bidwell & Associates Ltd. purchased a new stake in shares of AngioDynamics during the second quarter valued at about $109,000. Thrivent Financial for Lutherans boosted its stake in shares of AngioDynamics by 7.0% in the second quarter. Thrivent Financial for Lutherans now owns 12,860 shares of the company’s stock valued at $185,000 after buying an additional 840 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of AngioDynamics by 1.5% in the second quarter. Arizona State Retirement System now owns 13,696 shares of the company’s stock valued at $197,000 after buying an additional 200 shares during the last quarter. AHL Partners LLP bought a new stake in shares of AngioDynamics during the second quarter valued at $253,000. Finally, American International Group Inc. boosted its stake in shares of AngioDynamics by 3.9% in the second quarter. American International Group Inc. now owns 19,991 shares of the company’s stock valued at $287,000 after buying an additional 754 shares during the last quarter. 69.29% of the stock is currently owned by hedge funds and other institutional investors.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Stock Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related stocks with our FREE daily email newsletter.